ArticleCancer discovery2024

AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.

Olivier Nolan-Stevaux et al.PubMed ↗Publisher ↗

No numbers read from the abstract.